RE:RE:RE:RE:RE:RE:RE:hope we’re not being set up for snobei, That is true but apebetalone in betomace is using patients with low HDL and diabetic which showed the best results in the phase 2 trial if i remember somewhere in the 77% relative risk reduction , so even half of that in a 3 point MACE would be very very good